Equities Analysts Issue Forecasts for VRDN FY2027 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Wedbush dropped their FY2027 earnings estimates for Viridian Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $3.77 for the year, down from their previous estimate of $3.81. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ FY2027 earnings at $3.77 EPS, FY2028 earnings at $9.42 EPS and FY2028 earnings at $9.42 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million.

VRDN has been the subject of several other research reports. Royal Bank of Canada upped their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating for the company. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Stock Down 1.5 %

NASDAQ VRDN opened at $15.29 on Friday. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The stock has a market cap of $1.21 billion, a PE ratio of -3.55 and a beta of 1.32. The firm has a 50-day simple moving average of $18.27 and a 200 day simple moving average of $19.63. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Institutional Trading of Viridian Therapeutics

Several large investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Viridian Therapeutics by 29.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company’s stock worth $2,220,000 after acquiring an additional 26,286 shares in the last quarter. Tang Capital Management LLC raised its position in Viridian Therapeutics by 11.1% in the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock valued at $47,789,000 after purchasing an additional 250,000 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in Viridian Therapeutics by 90.8% in the fourth quarter. Rafferty Asset Management LLC now owns 172,960 shares of the company’s stock worth $3,316,000 after purchasing an additional 82,309 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock worth $395,000 after purchasing an additional 8,761 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in shares of Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock valued at $20,850,000 after buying an additional 662,634 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.